Doxorubicin-Induced Oxidative Stress Differentially Regulates Proteolytic Signaling in Cardiac and Skeletal Muscle.
Doxorubicin (DOX) is a highly effective antineoplastic agent used in cancer treatment. Unfortunately, clinical use of DOX is limited due to the development of dose-dependent toxicity to cardiac and respiratory (i.e. diaphragm) muscles. Following administration, DOX preferentially localizes to the inner mitochondrial membrane where it promotes cellular toxicity via enhanced mitochondrial ROS production. Although recent evidence suggests that ameliorating mitochondrial ROS emission preserves cardiorespiratory muscle function following DOX treatment, the mechanisms responsible for this protection remain unknown. Therefore, we tested the hypothesis that DOX-induced mitochondrial ROS production is required to stimulate pathological signaling by the autophagy/lysosomal system (ALS), the ubiquitin-proteasome pathway (UPP), and the unfolded protein response (UPR). Cause and effect were determined by administration of the mitochondrial-targeted peptide SS-31 to DOX-treated animals. Interestingly, while SS-31 abrogated aberrant mitochondrial ROS emission in cardiorespiratory muscles of DOX-treated animals, our results revealed muscle-specific regulation of effector pathways. In the heart, SS-31 prevented DOX-induced proteolytic signaling through the ALS and UPP. In contrast, ALS signaling was inhibited by SS-31 in the diaphragm, but the UPP was not affected. UPR signaling was activated in both muscles at eIF2a-S51 in the heart and diaphragm of DOX-treated animals and was attenuated with SS-31 treatment in both tissues. However, downstream signaling of eIF2α (ATF4 and CHOP) was diminished in the heart but upregulated in the diaphragm with DOX. Collectively, these results show that DOX-induced mitochondrial ROS plays distinct roles in the regulation of cardiac and diaphragm muscle proteolysis.